Refractory/recurrent acute myeloid leukemia
Conditions
Interventions
Experimental group:Bridging allogeneic hematopoietic stem cell transplantation
Sponsors
Beijing GoBroad Boren Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 75 Years
Inclusion criteria
Inclusion criteria: 1. Relapsed/refractory acute myeloid leukemia patients in remission after treatment with CD33-CART, CD123-CART, or CD371-CART; 2. No gender limit; 3. Aged =60 days; 7. Children under 8 years old shall sign the informed consent voluntarily by their legal representatives (guardians); children between 8 and 18 years old who have the ability to know themselves and their legal representatives (guardians) shall sign the informed consent voluntarily; adults over 18 years old shall sign the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Intracranial hypertension or cerebral disturbance of consciousness; 2. Symptomatic heart failure or severe arrhythmia; 3. Symptoms of severe respiratory failure; 4. With other types of malignant tumors; 5. Diffuse vascular intravascular coagulation; 6. Serum creatinine and/or urea nitrogen >= 1.5 times the normal value; 7. Suffering from sepsis or other hard-to-control infections; 8. Have uncontrolled diabetes; 9. Severe mental disorder; 10. Cranial MRI examination showed obvious lesions in the skull; 11. Have received organ transplantation (excluding bone marrow transplantation); 12. The blood HCG test of female patients (fertile patients) is positive; 13. Screening positive for hepatitis (including hepatitis B and C) and HIV/AIDS and syphilis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment-Related Mortality;Treatment-Related Adverse Events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Complete Remission;Partial Remission;Duration of Response;Progression-Free Survival;Overall Survival; | — |
Countries
China
Contacts
Public ContactSong Yanzhi
Beijing GoBroad Boren Hospital
Outcome results
None listed